NCBI Taxonomy: 2017

Streptoalloteichus hindustanus (ncbi_taxid: 2017)

found 9 associated metabolites at species taxonomy rank level.

Ancestor: Streptoalloteichus

Child Taxonomies: none taxonomy data.

Tobramycin

(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol

C18H37N5O9 (467.2591)


Tobramycin is only found in individuals that have used or taken this drug. It is an aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10\\\% component of the antibiotic complex, nebramycin, produced by the same species. [PubChem]Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Tobramycin (Nebramycin Factor 6) is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms[1].Tobramycin can be used to pneumonia research caused by Pseudomonas aeruginosa[2][3].

   

Tobramycin

Tobramycin

C18H37N5O9 (467.2591)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring. S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Tobramycin (Nebramycin Factor 6) is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms[1].Tobramycin can be used to pneumonia research caused by Pseudomonas aeruginosa[2][3].

   

2-(2,3-dimethoxyphenyl)-n-[(2s)-2-hydroxy-2-phenylethyl]-5-methyl-1,3-oxazole-4-carboximidic acid

2-(2,3-dimethoxyphenyl)-n-[(2s)-2-hydroxy-2-phenylethyl]-5-methyl-1,3-oxazole-4-carboximidic acid

C21H22N2O5 (382.1529)


   

2-(2-hydroxy-3-methoxyphenyl)-n-[2-(2-hydroxyphenyl)ethyl]-5-methyl-1,3-oxazole-4-carboximidic acid

2-(2-hydroxy-3-methoxyphenyl)-n-[2-(2-hydroxyphenyl)ethyl]-5-methyl-1,3-oxazole-4-carboximidic acid

C20H20N2O5 (368.1372)


   

2-(2,3-dimethoxyphenyl)-n-(2-hydroxy-2-phenylethyl)-5-methyl-1,3-oxazole-4-carboximidic acid

2-(2,3-dimethoxyphenyl)-n-(2-hydroxy-2-phenylethyl)-5-methyl-1,3-oxazole-4-carboximidic acid

C21H22N2O5 (382.1529)


   

2-(2,3-dimethoxyphenyl)-n-[2-(2-hydroxyphenyl)ethyl]-5-methyl-1,3-oxazole-4-carboximidic acid

2-(2,3-dimethoxyphenyl)-n-[2-(2-hydroxyphenyl)ethyl]-5-methyl-1,3-oxazole-4-carboximidic acid

C21H22N2O5 (382.1529)


   

2-(2-hydroxy-3-methoxyphenyl)-5-methyl-n-(2-phenylethyl)-1,3-oxazole-4-carboximidic acid

2-(2-hydroxy-3-methoxyphenyl)-5-methyl-n-(2-phenylethyl)-1,3-oxazole-4-carboximidic acid

C20H20N2O4 (352.1423)


   

(2r,3r,4s,5s,6s)-2-{[(2r,3s,4r,4ar,7r,8as)-7-amino-6-{[(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy}-4-hydroxy-3-(methylamino)-octahydropyrano[3,2-b]pyran-2-yl]oxy}-5-amino-6-(hydroxymethyl)oxane-3,4-diol

(2r,3r,4s,5s,6s)-2-{[(2r,3s,4r,4ar,7r,8as)-7-amino-6-{[(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy}-4-hydroxy-3-(methylamino)-octahydropyrano[3,2-b]pyran-2-yl]oxy}-5-amino-6-(hydroxymethyl)oxane-3,4-diol

C21H41N5O11 (539.2802)


   

3-amino-6-{[(2-{2-[2-({2-[(4-{[2-({[2-(1-{[2-amino-2-(c-hydroxycarbonimidoyl)ethyl]amino}-2-(c-hydroxycarbonimidoyl)ethyl)-6-imino-5-methyl-1h-pyrimidin-4-yl](hydroxy)methylidene}amino)-3-[(3-{[3,5-dihydroxy-4-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-1-hydroxy-3-(3h-imidazol-4-yl)propylidene]amino}-1,3-dihydroxypentylidene)amino]-1,3-dihydroxybutylidene}amino)-2-[(5-amino-3,4-dihydroxy-6-methyloxan-2-yl)oxy]-1-hydroxyethyl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)(hydroxy)methylidene]amino}-n-{3-[(4-aminobutyl)amino]propyl}hexanimidic acid

3-amino-6-{[(2-{2-[2-({2-[(4-{[2-({[2-(1-{[2-amino-2-(c-hydroxycarbonimidoyl)ethyl]amino}-2-(c-hydroxycarbonimidoyl)ethyl)-6-imino-5-methyl-1h-pyrimidin-4-yl](hydroxy)methylidene}amino)-3-[(3-{[3,5-dihydroxy-4-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-1-hydroxy-3-(3h-imidazol-4-yl)propylidene]amino}-1,3-dihydroxypentylidene)amino]-1,3-dihydroxybutylidene}amino)-2-[(5-amino-3,4-dihydroxy-6-methyloxan-2-yl)oxy]-1-hydroxyethyl]-1,3-thiazol-4-yl}-1,3-thiazol-4-yl)(hydroxy)methylidene]amino}-n-{3-[(4-aminobutyl)amino]propyl}hexanimidic acid

C68H110N22O27S2 (1730.7352)